Evidence map›Paper›PMID 23681227›Full record

ArticleCell death & disease2013

IP3R2 levels dictate the apoptotic sensitivity of diffuse large B-cell lymphoma cells to an IP3R-derived peptide targeting the BH4 domain of Bcl-2.

H Akl, G Monaco, R La Rovere, K Welkenhuyzen, S Kiviluoto, T Vervliet, J Molgó, C W Distelhorst, L Missiaen, K Mikoshiba and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 108 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Bcl-xL acts as an inhibitor of IPCell death and differentiation · 2022
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. IPProgress in molecular and subcellular biology · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Bcl-2-Protein Family as Modulators of IPCold Spring Harbor perspectives in biology · 2020
    Review
  15. Calcium Permeable Channels in Cancer Hallmarks.Frontiers in pharmacology · 2020
    Review
  16. Relevance of Membrane Contact Sites in Cancer Progression.Frontiers in cell and developmental biology · 2020
    Review
  17. Partners in Crime: Towards New Ways of Targeting Calcium Channels.International journal of molecular sciences · 2019
    Review
  18. Review
  19. Article
  20. Constitutive IPCell death and differentiation · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 5 countries.

H AklLaboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
G Monaco
R La Rovere
K Welkenhuyzen
S Kiviluoto
T Vervliet
J Molgó
C W Distelhorst
L Missiaen
K Mikoshiba
J B Parys
H De Smedt
G Bultynck
VIB-KU Leuven Center for Cancer Biology · BECentre National de la Recherche Scientifique · FRRIKEN Center for Brain Science · JPUniversity Hospitals of Cleveland · USUniversity of Chieti-Pescara · IT

Funding

Bcl-2 function on the endoplasmic reticulumR01CA085804 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI DISTELHORST, CLARK W · 2000 to 2014
$3.7M
NCI NIH HHS R01 CA085804
6 · The paper itself

Abstract

Disrupting inositol 1,4,5-trisphosphate (IP3) receptor (IP3R)/B-cell lymphoma 2 (Bcl-2) complexes using a cell-permeable peptide (stabilized TAT-fused IP3R-derived peptide (TAT-IDP(S))) that selectively targets the BH4 domain of Bcl-2 but not that of B-cell lymphoma 2-extra large (Bcl-Xl) potentiated pro-apoptotic Ca(2+) signaling in chronic lymphocytic leukemia cells. However, the molecular mechanisms rendering cancer cells but not normal cells particularly sensitive to disrupting IP3R/Bcl-2 complexes are poorly understood. Therefore, we studied the effect of TAT-IDP(S) in a more heterogeneous Bcl-2-dependent cancer model using a set of 'primed to death' diffuse large B-cell lymphoma (DL-BCL) cell lines containing elevated Bcl-2 levels. We discovered a large heterogeneity in the apoptotic responses of these cells to TAT-IDP(S) with SU-DHL-4 being most sensitive and OCI-LY-1 being most resistant. This sensitivity strongly correlated with the ability of TAT-IDP(S) to promote IP3R-mediated Ca(2+) release. Although total IP3R-expression levels were very similar among SU-DHL-4 and OCI-LY-1, we discovered that the IP3R2-protein level was the highest for SU-DHL-4 and the lowest for OCI-LY-1. Strikingly, TAT-IDP(S)-induced Ca(2+) rise and apoptosis in the different DL-BCL cell lines strongly correlated with their IP3R2-protein level, but not with IP3R1-, IP3R3- or total IP3R-expression levels. Inhibiting or knocking down IP3R2 activity in SU-DHL-4-reduced TAT-IDP(S)-induced apoptosis, which is compatible with its ability to dissociate Bcl-2 from IP3R2 and to promote IP3-induced pro-apoptotic Ca(2+) signaling. Thus, certain chronically activated B-cell lymphoma cells are addicted to high Bcl-2 levels for their survival not only to neutralize pro-apoptotic Bcl-2-family members but also to suppress IP3R hyperactivity. In particular, cancer cells expressing high levels of IP3R2 are addicted to IP3R/Bcl-2 complex formation and disruption of these complexes using peptide tools results in pro-apoptotic Ca(2+) signaling and cell death.

Indexed as

ApoptosisCalciumCell Line, TumorHumansInositol 1,4,5-Trisphosphate ReceptorsLeukemia, Lymphocytic, Chronic, B-CellPeptidesProtein BindingProtein IsoformsProtein Structure, TertiaryProto-Oncogene Proteins c-bcl-2RNA InterferenceRNA, Small InterferingCalciumInositol 1,4,5-Trisphosphate ReceptorsPeptidesProtein IsoformsProto-Oncogene Proteins c-bcl-2RNA, Small Interfering

Identifiers

PMID23681227
PMCPMC3674349
OpenAlexW1998447416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.